These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32597867)

  • 1. A Patient-Derived Xenograft Model for Venous Malformation.
    Schrenk S; Goines J; Boscolo E
    J Vis Exp; 2020 Jun; (160):. PubMed ID: 32597867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Xenograft Model for Venous Malformation.
    Goines J; Boscolo E
    Methods Mol Biol; 2021; 2206():179-192. PubMed ID: 32754818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A xenograft model for venous malformation.
    Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
    Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
    Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
    Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation.
    Li X; Cai Y; Goines J; Pastura P; Brichta L; Lane A; Le Cras TD; Boscolo E
    Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):496-512. PubMed ID: 30626204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.
    Le Cras TD; Goines J; Lakes N; Pastura P; Hammill AM; Adams DM; Boscolo E
    Angiogenesis; 2020 Aug; 23(3):425-442. PubMed ID: 32350708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.
    Boscolo E; Limaye N; Huang L; Kang KT; Soblet J; Uebelhoer M; Mendola A; Natynki M; Seront E; Dupont S; Hammer J; Legrand C; Brugnara C; Eklund L; Vikkula M; Bischoff J; Boon LM
    J Clin Invest; 2015 Sep; 125(9):3491-504. PubMed ID: 26258417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic Activating PIK3CA Mutations Cause Venous Malformation.
    Limaye N; Kangas J; Mendola A; Godfraind C; Schlögel MJ; Helaers R; Eklund L; Boon LM; Vikkula M
    Am J Hum Genet; 2015 Dec; 97(6):914-21. PubMed ID: 26637981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the endothelial pathogenic mechanism of TIE2-related venous malformation.
    Du Z; Zheng J; Zhang Z; Wang Y
    J Vasc Surg Venous Lymphat Disord; 2017 Sep; 5(5):740-748. PubMed ID: 28818232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic Loss-of-Function PIK3R1 and Activating Non-hotspot PIK3CA Mutations Associated with Capillary Malformation with Dilated Veins (CMDV).
    De Bortoli M; Queisser A; Pham VC; Dompmartin A; Helaers R; Boutry S; Claus C; De Roo AK; Hammer F; Brouillard P; Abdelilah-Seyfried S; Boon LM; Vikkula M
    J Invest Dermatol; 2024 Sep; 144(9):2066-2077.e6. PubMed ID: 38431221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive phenotypic and genomic characterization of venous malformations.
    Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E
    Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
    di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
    Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic PIK3CA mutations as a driver of sporadic venous malformations.
    Castel P; Carmona FJ; Grego-Bessa J; Berger MF; Viale A; Anderson KV; Bague S; Scaltriti M; Antonescu CR; Baselga E; Baselga J
    Sci Transl Med; 2016 Mar; 8(332):332ra42. PubMed ID: 27030594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of lysyl oxidase in venous malformations: Association with vascular destabilization and sclerotherapy.
    Zhu J; Shao M; Guo F; Ren J; Tang Z; Geng J; Xu Z; Jia J; Chen L; Jia Y
    J Dermatol; 2020 May; 47(5):518-526. PubMed ID: 32162383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations.
    Moneghini L; Tosi D; Graziani D; Caretti A; Colletti G; Baraldini V; Cattaneo E; Spaccini L; Zocca A; Bulfamante GP
    Hum Pathol; 2020 May; 99():98-106. PubMed ID: 32272124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic landscape of common venous malformations in the head and neck.
    Du Z; Liu JL; You YH; Wang LZ; He J; Zheng JW; Zhang ZY; Wang YA
    J Vasc Surg Venous Lymphat Disord; 2021 Jul; 9(4):1007-1016.e7. PubMed ID: 33248299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component.
    Jauhiainen S; Ilmonen H; Vuola P; Rasinkangas H; Pulkkinen HH; Keränen S; Kiema M; Liikkanen JJ; Laham-Karam N; Laidinen S; Beter M; Aavik E; Lappalainen K; Lohi J; Aronniemi J; Örd T; Kaikkonen MU; Salminen P; Tukiainen E; Ylä-Herttuala S; Laakkonen JP
    Elife; 2023 May; 12():. PubMed ID: 37199488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive Active Mutant TIE2 Induces Enlarged Vascular Lumen Formation with Loss of Apico-basal Polarity and Pericyte Recruitment.
    Cai Y; Schrenk S; Goines J; Davis GE; Boscolo E
    Sci Rep; 2019 Aug; 9(1):12352. PubMed ID: 31451744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Molecular Therapies for Venous Malformations.
    Kangas J; Nätynki M; Eklund L
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():6-19. PubMed ID: 29668117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular heterogeneity and immune microenvironment revealed by single-cell transcriptome in venous malformation and cavernous venous malformation.
    Li Y; Yang J; Huang Y; Ge S; Song X; Jia R; Wang Y
    J Mol Cell Cardiol; 2022 Jan; 162():130-143. PubMed ID: 34536440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.